Switch to:
Also traded in: Germany, Israel, Mexico

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

Weekly CEO Buys Highlights Citigroup, Opko, JMP Group, Tuesday Morning, Calamos lead list, according to GuruFocus Insider Data
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair These are the largest CEO buys during the past week, according to GuruFocus' Insider Data
These are the largest CEO buys during the past week, according to GuruFocus' Insider Data. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB A look at recent insider buys from CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals GuruFocus Insider Data identifies CEOs' largest buys in the past week.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY A roundup of recent insider buys
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
» More Articles for OPK

Ratios

vs
industry
vs
history
Forward P/E 17.76
OPK's Forward P/E is ranked higher than
55% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 19.53 vs. OPK: 17.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.28
OPK's P/B is ranked higher than
64% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. OPK: 2.28 )
Ranked among companies with meaningful P/B only.
OPK' s P/B Range Over the Past 10 Years
Min: 2.22  Med: 8.87 Max: 50.6
Current: 2.28
2.22
50.6
P/S 16.52
OPK's P/S is ranked lower than
63% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. OPK: 16.52 )
Ranked among companies with meaningful P/S only.
OPK' s P/S Range Over the Past 10 Years
Min: 15.25  Med: 34.80 Max: 126.5
Current: 16.52
15.25
126.5
PFCF 26.65
OPK's PFCF is ranked higher than
58% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 30.47 vs. OPK: 26.65 )
Ranked among companies with meaningful PFCF only.
OPK' s PFCF Range Over the Past 10 Years
Min: 25.94  Med: 36.39 Max: 49.65
Current: 26.65
25.94
49.65
POCF 24.29
OPK's POCF is ranked higher than
57% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. OPK: 24.29 )
Ranked among companies with meaningful POCF only.
OPK' s POCF Range Over the Past 10 Years
Min: 23.65  Med: 34.29 Max: 48.23
Current: 24.29
23.65
48.23
Current Ratio 1.45
OPK's Current Ratio is ranked lower than
82% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. OPK: 1.45 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.93 Max: 415
Current: 1.45
0.88
415
Quick Ratio 1.33
OPK's Quick Ratio is ranked lower than
80% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OPK: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 5.29 Max: 415
Current: 1.33
0.48
415
Days Inventory 79.17
OPK's Days Inventory is ranked higher than
68% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. OPK: 79.17 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 131.84  Med: 255.62 Max: 500.07
Current: 79.17
131.84
500.07
Days Sales Outstanding 287.25
OPK's Days Sales Outstanding is ranked lower than
93% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OPK: 287.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 163.92 Max: 727.85
Current: 287.25
38.86
727.85
Days Payable 273.60
OPK's Days Payable is ranked higher than
87% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. OPK: 273.60 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 66.48  Med: 118.54 Max: 1499.3
Current: 273.6
66.48
1499.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.99
OPK's Price/Projected FCF is ranked higher than
56% of the 150 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. OPK: 2.99 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.04  Med: 14.63 Max: 236.67
Current: 2.99
3.04
236.67
Price/Median PS Value 0.47
OPK's Price/Median PS Value is ranked higher than
80% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. OPK: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 1.31 Max: 9.86
Current: 0.47
0.32
9.86
Price/Graham Number 5.36
OPK's Price/Graham Number is ranked lower than
83% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. OPK: 5.36 )
Ranked among companies with meaningful Price/Graham Number only.
OPK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.26  Med: 4.70 Max: 17.57
Current: 5.36
1.26
17.57
Earnings Yield (Greenblatt) (%) -3.60
OPK's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. OPK: -3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.03  Med: 0.00 Max: 0
Current: -3.6
-7.03
0

More Statistics

Revenue(Mil) $241
EPS $ -0.22
Beta1.82
Short Percentage of Float30.59%
52-Week Range $7.12 - 19.20
Shares Outstanding(Mil)545.01

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 469 1,090 1,512 2,153
EPS($) -0.13 0.04 0.47 0.97
EPS without NRI($) -0.13 0.04 0.47 0.97

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Jan 26 2016 
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair Jan 11 2016 
Weekly CEO Buys Highlights for the Final Week of 2015 Jan 04 2016 
Weekly CEO Buys Highlight: Prospect Capital, Sears Holdings, Calamos Asset Management, Opko Health, Dec 28 2015 
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB Nov 02 2015 
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals Oct 16 2015 
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY Sep 12 2015 
Weekly CEO Buys Highlight: Shutterstock, Endurance Specialty Holdings, Opko, Air Products, KapStone Aug 31 2015 
Top Insider Buys of the Week Aug 28 2015 
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings Aug 24 2015 

More From Other Websites
Fitbit, Tesla Lead List Of Hot Stocks In Short-Selling Circles Feb 05 2016
A Company's First Profit Can Mean Big Profits to Investors Jan 26 2016
Weekly CEO Buys Highlights Jan 26 2016
Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health Jan 25 2016
OPKO’s GeneDx to Present at Personalized Medicine World Conference Jan 22 2016
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair Jan 11 2016
OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference Jan 06 2016
OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference Jan 06 2016
OPKO HEALTH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2016
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes Jan 05 2016
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes Jan 05 2016
Weekly CEO Buys Highlights for the Final Week of 2015 Jan 04 2016
OPKO Health, Inc. breached its 50 day moving average in a Bullish Manner : December 30, 2015 Dec 30 2015
Weekly CEO Buys Highlight: Prospect Capital, Sears Holdings, Calamos Asset Management, Opko ... Dec 28 2015
OPKO’s GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer... Dec 21 2015
OPKO Health, Inc. – Value Analysis (NYSE:OPK) : December 15, 2015 Dec 15 2015
OPKO Health, Inc. breached its 50 day moving average in a Bearish Manner : December 15, 2015 Dec 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK